Skip to Main Content

An off-the-shelf CAR-T cell therapy developed by CRISPR Therapeutics induced complete remissions in some patients with advanced B-cell lymphoma, but a patient death was also deemed to be related to the treatment, the company said Wednesday.

The clinical trial results are preliminary and represent an effort by CRISPR Therapeutics to expand CRISPR-edited treatments into cancer care. The company, in partnership with Vertex Pharmaceuticals, is also conducting clinical trials of CRISPR-based therapies for patients with rare, inherited blood disorders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED